Jose M Gatell

Summary

Publications

  1. pmc The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:353-63. 2010
  2. doi Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010
  3. pmc Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes
    Soo Yon Rhee
    Department of Medicine, Stanford University, Stanford, CA, USA
    AIDS Res Ther 9:13. 2012
  4. pmc The use of integrase inhibitors in treatment-experienced patients
    Jose M Gatell
    Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Eur J Med Res 14:30-5. 2009
  5. ncbi Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy
    Esteban Martinez
    Infectious Diseases, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Antivir Ther 9:649-63. 2004
  6. doi When and why to start antiretroviral therapy?
    Jose M Gatell
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    J Antimicrob Chemother 65:383-5. 2010
  7. ncbi Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results
    Jose Gatell
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 44:1484-92. 2007
  8. ncbi [Secondary effects associated with raltegravir]
    Jose M Gatell
    Servicio de Infecciones, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:34-9. 2008
  9. ncbi [Efficacy of raltegravir: from healthy volunteers to phase III trials]
    Jose M Gatell
    Servicio de Infecciones, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:29-33. 2008
  10. ncbi Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine
    Elena Ferrer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    J Infect Dis 187:687-90. 2003

Detail Information

Publications87

  1. pmc The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:353-63. 2010
    ..To assess the effects of decreased antiretroviral therapy exposure on body fat and metabolic parameters...
  2. doi Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010
    ..Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids...
  3. pmc Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes
    Soo Yon Rhee
    Department of Medicine, Stanford University, Stanford, CA, USA
    AIDS Res Ther 9:13. 2012
    ..abstract:..
  4. pmc The use of integrase inhibitors in treatment-experienced patients
    Jose M Gatell
    Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Eur J Med Res 14:30-5. 2009
    ..Most likely explanation was the presence of archived resistance mutationts to background therapy leading to a functional monotherapy with raltegravir...
  5. ncbi Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy
    Esteban Martinez
    Infectious Diseases, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Antivir Ther 9:649-63. 2004
    ..Development of new PIs with more favourable effects on the lipid profile should be of benefit...
  6. doi When and why to start antiretroviral therapy?
    Jose M Gatell
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    J Antimicrob Chemother 65:383-5. 2010
    ..Willingness to be treated and to adhere to the prescribed medication still remains the key to success...
  7. ncbi Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results
    Jose Gatell
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 44:1484-92. 2007
    ..Limited data are available on the usefulness of switching from a PI-based regimen to a regimen based on a different PI, such as atazanavir, in HIV-infected patients experiencing virologic suppression but seeking regimen simplification...
  8. ncbi [Secondary effects associated with raltegravir]
    Jose M Gatell
    Servicio de Infecciones, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:34-9. 2008
    ..The most notable were diarrhea, nausea and headache. The lipid profile of raltegravir was better than that of efavirenz. In view of the above, the risk-benefit ratio for raltegravir is positive...
  9. ncbi [Efficacy of raltegravir: from healthy volunteers to phase III trials]
    Jose M Gatell
    Servicio de Infecciones, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:29-33. 2008
    ..For all these reasons, raltegravir is an attractive option in treatment-naive and pretreated patients and in those receiving simplification regimens...
  10. ncbi Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine
    Elena Ferrer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    J Infect Dis 187:687-90. 2003
    ..At failure, mutations were detected in 7 of 16 patients. An agreement in the results of virtual and real phenotypes was observed in the 93 samples in which both tests were performed...
  11. ncbi Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection
    Felipe Garcia
    Clinic Institute of Infections and Immunology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    AIDS 16:1761-5. 2002
    ..The objective was to analyse which baseline factors could predict a favourable outcome after structured therapy interruption (STI)...
  12. ncbi Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine
    Carme Vidal
    Microbiology Laboratory, Institut Clínic de Infeccions i Immunologia, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    Antivir Ther 7:283-7. 2002
    ....
  13. ncbi Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients
    Agnes Libois
    Infectious Diseases Unit, School of Medicine, University of Barcelona, Spain
    AIDS Res Hum Retroviruses 22:657-66. 2006
    ..Conversely, higher and longer viral replication after cessation of HAART overwhelms the immune system. These data may help to guide future immune-based therapies...
  14. ncbi Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor
    Jose L Blanco
    Infectious Diseases Service, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    AIDS 19:829-31. 2005
    ..Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs...
  15. ncbi A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study
    Felipe Garcia
    Infectious Diseases Unit, Clinic Institute of Infectious Diseases and Immunology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    AIDS 17:43-51. 2003
    ....
  16. ncbi Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir
    Olga Millán
    Servei Immunologia, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Clin Pharmacokinet 44:525-38. 2005
    ..Due to the low doses involved, pharmacokinetic-pharmacodynamic monitoring is recommended...
  17. doi Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients
    Pedro Castro
    Medical Intensive Care Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 25:1249-59. 2009
    ..However, it induced an increase in T cell activation and a drop in CD4(+) T cells, although these changes did not influence the VL rebound dynamics after HAART interruption...
  18. doi Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:F1-9. 2010
    ..To assess the effects of initiating abacavir-containing therapy on plasma lipids and cardiovascular biomarkers...
  19. ncbi A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
    Esteban Martinez
    Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, Spain
    J Acquir Immune Defic Syndr 51:290-7. 2009
    ..We compared 48-week efficacy and safety of these combinations as substitutes of nucleosides in patients with virological suppression...
  20. ncbi Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine
    Anna Lopez
    Retrovirology and Viral Immunopathology Laboratory, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Vaccine 27:6166-78. 2009
    ..Taken together, heterogeneity in the maturation status of HIV-specific CD8 T cells may be partially involved in the drop of peptide-specific IFN-gamma production during immunizations...
  21. ncbi Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
    ..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation...
  22. ncbi Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy
    Pilar Navarrete
    Infectious Diseases Unit, Clinic Institute of Infectious Diseases and Immunology, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    Antivir Ther 8:635-7. 2003
    ..No correlation was observed after 1 year of antiretroviral therapy. A protease inhibitor-containing regimen was the best predictor of good tonsillar tissue virological response...
  23. ncbi Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)
    Omar Sued
    Servicios de Enfermedades Infecciosas, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer IDIBAPS, Universidad de Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Enferm Infecc Microbiol Clin 24:238-44. 2006
    ..To describe the epidemiological and clinical characteristics and the evolution of a cohort of patients with primary HIV-1 infection from the Barcelona area...
  24. ncbi Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression
    Alex Soriano
    Institut Clinic d Infeccions i Immunologia, Hospital Clinic Universitari, Barcelona, Spain
    J Infect Dis 186:922-31. 2002
    ..EU subjects with sexual exposure to HIV-1, but not EU hemophiliacs, showed an underpresentation of SDF1-3'A allele frequency, which was coupled with high plasma SDF-1 levels and low CXCR4 expression...
  25. pmc Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals
    Víctor Casanova
    Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, Spain
    PLoS ONE 7:e51287. 2012
    ..Taken together, these findings suggest that ADA would promote enhanced and correctly polarized T-cell responses in strategies targeting asymptomatic HIV-infected individuals...
  26. doi Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz T
    Jose M Miro
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 26:747-57. 2010
    ..At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen...
  27. doi Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients
    Miriam J Alvarez-Martinez
    Hospital Clínic IDIBAPS Institut d Investigació August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    Diagn Microbiol Infect Dis 68:60-5. 2010
    ..However, their presence did not worsen prognosis of PcP. The response to TMP-SMX with therapeutic doses was successful in most cases...
  28. doi Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV
    Nuria Climent
    Hospital Clinic, Barcelona, Spain
    Immunol Cell Biol 87:634-9. 2009
    ..As IFN-gamma, TNF-alpha and IL-6 promote the Th1 versus Th2 phenotype and improve T helper proliferation responses and antigen-specific CTL responses ADA may be considered a promising candidate for therapeutic vaccine adjuvant...
  29. ncbi Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine
    Montserrat Plana
    Institut Clinic d Infeccions i Immunologia, Immunology, Infectious Diseases and Microbiology Units, Institut de Investigació Biomèdica Agusti Pi i Suñer, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Antivir Ther 9:197-204. 2004
    ..To evaluate the immunological response in HIV-1-infected, antiretroviral-naive patients receiving highly active antiretroviral therapy regimen of two nucleosides plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor...
  30. ncbi Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption
    Eric Florence
    Unit of Infectious Diseases, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    Clin Infect Dis 39:569-74. 2004
    ..In conclusion, approximately 2 years after STI, only a low proportion of patients who had a good immunological profile at the end of the STI period still had a good virological response...
  31. ncbi Glutamate released by dendritic cells as a novel modulator of T cell activation
    Rodrigo Pacheco
    Department of Biochemistry and Molecular Biology, Faculty of Biology and Institut d Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    J Immunol 177:6695-704. 2006
    ..These data suggest that, during T cell-DC interaction, glutamate is a novel and highly effective regulator in the initiation of T cell-mediated immune responses...
  32. ncbi Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Juan A Arnaiz
    Hospital Clinic IDIBAPS, University of Barcelona, Spain
    AIDS 17:831-40. 2003
    ....
  33. doi Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Esteban Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Spain
    AIDS 26:2315-26. 2012
    ..Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this strategy affects plasma biomarkers associated with atherosclerosis is unknown...
  34. ncbi Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients
    Pedro Castro
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Spain
    AIDS Res Hum Retroviruses 23:863-7. 2007
    ..HCV-treated LTNP could have a worse HIV progression than HIV-HCV-treated NP or untreated coinfected LTNP. HCV infection does not have a deleterious effect on the progression of LTNP...
  35. ncbi HIV-1 upregulates intercellular adhesion molecule-1 gene expression in lymphoid tissue of patients with chronic HIV-1 infection
    Marta Garrido
    Department of Pathology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 46:268-74. 2007
    ..Our main objective was to study ICAM-1 expression in LT from HIV-1-infected persons and to correlate this expression with LT viral load and the immunoarchitecture alteration before and after highly active antiretroviral therapy (HAART)...
  36. doi Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  37. pmc Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression
    Marta Rodríguez-García
    Service of Immunology, Hospital Clinic de Barcelona, Barcelona, Spain
    PLoS ONE 5:e9436. 2010
    ..Since DC-HIV interaction plays a critical role during the first steps of HIV infection, we investigated the possible impact of alpha-defensins1-3 production by DC on disease progression...
  38. pmc Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus
    Francesc Marco
    Microbiology Service, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain
    Antimicrob Agents Chemother 52:2538-43. 2008
    ..01). No statistically significant difference between the vancomycin HD and the vancomycin RD for MRSA treatment was noted. These results support the use of daptomycin for the treatment of aortic valve endocarditis caused by GISA and MRSA...
  39. pmc Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion
    Mar Naranjo-Gómez
    Laboratory of Immunobiology for Research and Diagnosis, Blood and Tissue Bank BST, Department of Cell Biology, Physiology and Immunology, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    Immunology 119:488-98. 2006
    ..These results show that tacrolimus treatment of PDCs impairs CpG-induced activation, which could affect the outcome of the immune response...
  40. doi Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption
    Agathe Leon
    Infectious Diseases Department, Hospital Clinic of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Antimicrob Chemother 63:184-8. 2009
    ..CD4+ T cell recovery dynamics were analysed during the 'on treatment' periods in structured therapy interruption (STI) as well as the long-term immune reconstitution with highly active antiretroviral therapy (HAART) after finishing STI...
  41. pmc Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors
    Alba Diaz
    Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    J Infect Dis 203:810-3. 2011
    ..047). To our knowledge, this is the first time that MMP/TIMP imbalance has been correlated with lymphoid tissue collagen deposition and incomplete immune recovery in HIV-infected patients, even after long-term antiretroviral treatment...
  42. doi Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study
    Carlos Cervera
    Service of Infectious Diseases, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Enferm Infecc Microbiol Clin 29:587-92. 2011
    ....
  43. ncbi Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation
    Anna Suy
    Gynecology Department, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    J Infect Dis 196:1191-201. 2007
    ....
  44. doi Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells
    José M Martinez-Navio
    Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain
    J Leukoc Biol 89:127-36. 2011
    ..These data suggest that ADA is a relevant modulator of CD4+ T cell differentiation, even in cells from immunologically compromised individuals...
  45. pmc Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation
    José M Martinez-Navio
    Department of Biochemistry and Molecular Biology, Faculty of Biology, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Immunology 128:393-404. 2009
    ....
  46. doi Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption
    Gabriel Mestre
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:1485-95. 2008
    ..This finding suggests that STI could decrease the number of NK subsets, which is related to the worst clinical development in these patients...
  47. ncbi Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality
    Miriam J Alvarez-Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Diagn Microbiol Infect Dis 62:34-43. 2008
    ..03 and P < 0.001, respectively). The prevalence of DHPS mutants in Spain is low and is not associated with a worse outcome. Severe respiratory failure at admission is the strongest predictor of PCP outcome...
  48. ncbi Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
    Felipe Garcia
    Clinic Institute of Infectious Diseases and Immunology, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 36:702-13. 2004
    ..It seems that the immune recovery slows down after approximately 3 years of HAART and reaches a plateau after 4-5 years of HAART...
  49. doi Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients
    Alba Ruiz
    Infectious Diseases Unit, Hospital Clinic, Villarroel 170, Barcelona, Spain
    Immunotherapy 1:347-54. 2009
    ..92, p = 0.03). If more than 20,000 ILDCs had migrated, they could have been detected. In future trials, a higher number of DCs or alternative methods should be used to assess the migration of DCs to lymph nodes...
  50. ncbi The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients
    Ana Milinkovic
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 12:407-15. 2007
    ..We assessed the safety and efficacy of reducing the dose of stavudine compared with switching to tenofovir or maintaining the standard dose of d4T...
  51. ncbi Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  52. pmc Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients
    Pedro Castro
    Medical Intensive Care Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 29:68-76. 2013
    ..After treatment interruption, they showed greater specific immune responses against HIV, which did not prevent a higher virological rebound. EIV between 20 and 200 copies/ml did not have this deleterious effect...
  53. doi Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
    Marylène Lejeune
    Immunology Service, Hospital Clinic Institut d Investigacions Biomèdiques Augustí Pi i Suñer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 52:662-70. 2011
    ..It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE)...
  54. ncbi Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3
    Montserrat Plana
    Clinic Institute of Infectious Diseases and Immunology, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 36:791-9. 2004
    ..To analyze the dynamics of both HIV-1-specific CD4 and CD8 T-cell responses during structured treatment interruptions (STIs) in chronically HIV-1-infected (CHI) patients and to correlate them with the viral set point achieved...
  55. ncbi Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study
    Felipe Garcia
    Infectious Diseases Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 36:823-30. 2004
    ..005) after 6 months off HAART. We found that combining MMF and HAART delayed VL rebound and improved control of viral replication without HAART but only when inhibition of lymphocyte proliferation was achieved...
  56. ncbi Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence
    Llucia Alos
    Department of Pathology, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Mod Pathol 18:127-36. 2005
    ..However, these parameters studied in lymphoid tissue are not re-established completely, even after 36 months of highly active antiretroviral therapy...
  57. ncbi Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy
    Anna Suy
    Obstetric and Gynecological Service, Hospital Clinic of the Institute of Biomedical Investigations, August Pi i Sunyer Hospital, University of Barcelona, Barcelona, Spain
    AIDS 20:59-66. 2006
    ..Pre-eclampsia and/or fetal death have increased sharply in HIV-infected pregnant women receiving HAART...
  58. doi Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects
    Marta Rodríguez-García
    Service of Immunology, Hospital Clinic Universitari de Barcelona, School of Medicine, University of Barcelona, Barcelona, Spain
    Clin Immunol 131:374-84. 2009
    ..Results suggest that alpha-defensins1-3 might modulate the maturation and differentiation of MDDCs in vivo and therefore could be of special interest in the field of vaccine development...
  59. pmc Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin
    Cristina Garcia-de-la-Maria
    Infectious Diseases Service, University of Barcelona, Barcelona, Spain
    Antimicrob Agents Chemother 57:2319-25. 2013
    ..In conclusion, HLDR develops rapidly and frequently in vitro and in vivo among mitis group streptococci. Combining daptomycin with gentamicin enhanced its activity and prevented the development of HLDR in most cases...
  60. doi Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women
    María Martínez-Rebollar
    Infectious Diseases Service, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ther Drug Monit 33:772-7. 2011
    ..No vertical transmissions were reported. Therapeutic drug monitoring of SQV during pregnancy should be considered, mainly during the third trimester, to ensure adequate drug exposure throughout the entire pregnancy...
  61. doi Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients
    Alba Diaz
    Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:2029-39. 2010
    ..The factors associated with fibrosis in lymphoid tissue in long-term treated HIV-infected patients and their correlation with immune reconstitution were assessed...
  62. ncbi Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy
    Xavier Badia
    Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Antivir Ther 9:979-85. 2004
    ..To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen...
  63. ncbi Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Calle Villarroel 170, 08036 Barcelona, Spain
    Lancet 364:65-7. 2004
    ..666, 95% CI 1.246-91.294, p=0.031). These results suggest that the risk of pancreatitis is heightened when didanosine and tenofovir are given together...
  64. doi [Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment]
    Jose M Miro
    Servicio de Enfermedades Infecciosas, Hospital Clinico IDIBAPS, Universidad de Barcelona, Barcelona, Spain
    Enferm Infecc Microbiol Clin 29:759-72. 2011
    ..No less important is the psychological support, as these patients must learn to live with a chronic infection, which managed properly can ensure a very good long-term prognosis and quality of life...
  65. ncbi [Specialized home care for infectious disease. Experience from 1995 to 2002]
    Juan Pablo Horcajada
    Servicio de Enfermedades Infecciosas, Hospital Clinic IDIBAPS, Universidad de Barcelona, IDIBAPS Institut d Investigacions Biomèdiques August Pi i Sunyer, Espana
    Enferm Infecc Microbiol Clin 25:429-36. 2007
    ..This study reviews the experience of this service from 1995 to 2002 using prospectively recorded data...
  66. ncbi Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection
    Felipe Garcia
    Infectious Diseases Unit, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Spain
    J Infect Dis 191:1680-5. 2005
    ..This response was associated with changes in HIV-1-specific CD4(+) lymphoproliferative and CD8(+) T cell responses. These changes were not observed in a group of nonimmunized control patients...
  67. ncbi Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study
    Jose M Gatell
    University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 53:456-63. 2010
    ..Raltegravir in combination therapy has demonstrated potent suppression of HIV-1 with a favorable safety profile. This report provides 96-week efficacy and safety data from Protocol 005, a Phase II study...
  68. doi Non-myeloablative hematopoietic stem cell transplantation in the treatment of severe idiopathic CD4+ lymphocytopenia
    Carlos Cervera
    Services of Infectious Diseases, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain
    Eur J Haematol 87:87-91. 2011
    ..Non-myeloablative allogeneic hematopoietic stem cell transplantation should be considered a treatment option for patients with severe forms of idiopathic CD4+ lymphocytopenia...
  69. ncbi Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis
    Felipe Garcia
    Infectious Diseases Unit, University of Barcelona, Barcelona, Spain
    Antivir Ther 7:195-7. 2002
    ..This antiretroviral regimen seems to have no effect on lymphocyte T cell subsets, however, it could have an immune-modulator role, inducing an increase in the proliferative responses to mitogens...
  70. doi Renal dysfunction in the setting of HIV/AIDS
    Jose M Miro
    Infectious Diseases Service, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr HIV/AIDS Rep 9:187-99. 2012
    ..This review focuses on clinical and epidemiological issues, treatment strategies (including dialysis and kidney transplantation), and recent advances among kidney disease in the HIV population...
  71. ncbi Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors
    Esteban Martinez
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Antivir Ther 8:403-10. 2003
    ..Whether a therapeutic approach addressed to those metabolic abnormalities may have any impact on body fat is not clear...
  72. pmc Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Esteban Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain
    AIDS Res Hum Retroviruses 29:235-41. 2013
    ..2744). The results of this analysis do not suggest that outcomes of abacavir/lamivudine are worse than those of tenofovir/emtricitabine when combined with raltegravir in virologically suppressed HIV-infected adults...
  73. ncbi Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study
    Alejandra Biglia
    Infectious Diseases Unit, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 39:1514-9. 2004
    ..The prevalence, risk factors, and potential hormonal abnormalities associated with gynecomastia in a cohort of HIV-infected men are poorly understood...
  74. ncbi [Inflammatory response in elderly patients with bacteremia]
    Luis Marti
    Servicio de Infecciones, Hospital Clinico IDIBAPS, Universidad de Barcelona, Barcelona, Spain
    Enferm Infecc Microbiol Clin 26:146-9. 2008
    ....
  75. ncbi Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3
    Marta Rodríguez-García
    Service of Immunology, Hospital Clinic Universitari de Barcelona, Villarroel 170, 08036, Barcelona, Spain
    J Leukoc Biol 82:1143-6. 2007
    ....
  76. ncbi Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens
    Miriam J Alvarez-Martinez
    Microbiology Department, Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona 08036, Spain
    Diagn Microbiol Infect Dis 56:153-60. 2006
    ..Real-time PCR has a statistically significantly better specificity than nested PCR (P = .015) and is likely to generate fewer false positives...
  77. doi Evaluation of the Roche COBAS® TaqMan® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue
    Cristina Gil
    AIDS Research Group IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Virol Methods 174:69-76. 2011
    ..The Roche COBAS® TaqMan® HIV-1 (HPS) test thereby proved to be a helpful tool for measuring the HIV-1 viral load in infected cells and lymphoid tissue reservoirs...
  78. pmc Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections
    Natividad Benito
    Service of Infectious Diseases, Institut Clínic de Infeccions i Inmunologia, Clinic Hospital IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    Clin Diagn Lab Immunol 11:608-14. 2004
    ..An elevated IL-8 level (>61 pg/ml) at the time of admission was an independent factor associated with higher mortality (odds ratio, 12; 95% confidence interval, 1.2 to 235.5)...
  79. ncbi Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors
    Montserrat Plana
    Institut Clínic de Infeccions i Immunologia ICII, Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    J Acquir Immune Defic Syndr 29:429-34. 2002
    ....
  80. ncbi Expression and function of the IL-2 receptor in activated human plasmacytoid dendritic cells
    Mar Naranjo-Gómez
    Laboratory of Immunobiology for Research and Applications to Diagnosis, Blood and Tissue Bank, Department of Cell Biology, Physiology and Immunology, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Immunol 37:1764-72. 2007
    ..Finally, CD25 expression may be considered as a useful early activation marker for human PDC...
  81. doi Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Hepatology 49:22-31. 2009
    ..47). Conclusion: In patients with HIV, HCV therapy with PEG 2b or PEG 2a plus RBV had no significant differences in efficacy and safety...
  82. pmc Health care-associated native valve endocarditis: importance of non-nosocomial acquisition
    Natividad Benito
    Hospital de Santa Creu i Sant Pau, University Autonoma of Barcelona, and Hospital Clínic IDIBAPS, University of Barcelona, Barcelona, Spain
    Ann Intern Med 150:586-94. 2009
    ..The clinical profile and outcome of nosocomial and non-nosocomial health care-associated native valve endocarditis are not well defined...
  83. ncbi Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    N Engl J Med 349:1036-46. 2003
    ..We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved...
  84. doi Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection
    Elena Herrera
    Unit of Synthesis and Biomedical Applications of Peptides IQAC CSIC, Barcelona, Spain
    J Med Chem 53:6054-63. 2010
    ..We also show how GBV-C E2 domains notably decrease cellular membrane fusion and interfere with the HIV-1 infectivity in a dose-dependent manner, highlighting their potential utility in future anti-HIV-1 therapies...
  85. ncbi Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS
    Alex Soriano
    Service of Infectious Diseases and AIDS Unit, Hospital Clinic de Barcelona, Villarroel, 170, 08036, Barcelona, Spain
    Immunogenetics 57:644-54. 2005
    ..Further studies are required to confirm these findings...
  86. doi Cardiovascular disease and HIV infection: host, virus, or drugs?
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Opin Infect Dis 22:28-34. 2009
    ..We review the risk of cardiovascular disease in HIV-infected persons compared with that in uninfected persons and discuss the relative contributions of host, HIV, and antiretroviral therapy in the light of current knowledge...
  87. pmc Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus
    Jose M Miro
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Antimicrob Agents Chemother 51:2373-7. 2007
    ..All isolates from vegetations remained susceptible to telavancin after therapy. The results suggest that telavancin may be an effective treatment for endocarditis caused by glycopeptide-intermediate S. aureus...